NCT07418749

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

An Open-label, Randomized, Controlled, Multicenter, Phase III Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 398 (estimated)
• Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main objective of this study is to evaluate the efficacy of SHR-A2102 versus investigator's choice of chemotherapy in patients with platinum-based chemotherapy and PD-(L)1 inhibitor treatment failed recurrent or metastatic cervical cancer.

Conditions

• Recurrent Cervical Cancer
• Metastatic Cervical Cancer

Interventions

Type	Name	Description
DRUG	SHR-A2102 for Injection	SHR-A2102 for injection.
DRUG	Pemetrexed Disodium for Injection	Pemetrexed Disodium for injection.
DRUG	Gemcitabine Hydrochloride for Injection	Gemcitabine Hydrochloride for injection.
DRUG	Topotecan Hydrochloride for Injection	Topotecan Hydrochloride for injection.
DRUG	Paclitaxel for Injection (Albumin bound)	Paclitaxel for injection (Albumin bound).

Timeline

• Start date: 2026-03-30
• Primary completion: 2027-12-01
• Completion: 2028-12-01
• First posted: 2026-02-18
• Last updated: 2026-04-06

Locations

1 site across 1 country: China